Reliable analytical methods are the foundation of every pharmaceutical development program, directly influencing decisions about drug substance quality, formulation performance, impurity control, and batch consistency. BOC Sciences provides integrated method development, validation, and transfer services that span the full method lifecycle—from early feasibility through formal validation and cross-laboratory implementation. Our scientists combine deep method development experience with broad analytical technology coverage to deliver methods that are purpose-built, rigorously validated, and ready for reliable use across different laboratories and testing environments.
Analytical method development, validation, and transfer are three interconnected stages that define the analytical lifecycle of a pharmaceutical product. Method development is the systematic process of designing and optimizing analytical procedures to measure critical quality attributes—such as assay, purity, impurity profile, dissolution, and residual content—with appropriate selectivity, sensitivity, and robustness. Method validation provides documented evidence that a developed method consistently performs as intended under defined conditions, confirming key performance characteristics. Method transfer ensures that a validated method can be reliably executed by a different laboratory, analyst, or instrument system while maintaining equivalent accuracy and precision. Together, these three stages form a continuous quality framework that supports drug substance characterization, formulation development, stability monitoring, and batch release testing across the product lifecycle.
BOC Sciences develops fit-for-purpose analytical methods tailored to the specific physicochemical properties of each drug substance, intermediate, and formulated product. Our analytical method optimization approach begins with a thorough understanding of the analyte structure, sample matrix, and intended application context.
When an existing method shows inadequate resolution, long run times, poor sensitivity, or inconsistent peak shape, we apply structured optimization strategies to improve method performance without starting from scratch.
BOC Sciences performs comprehensive method validation studies that generate documented evidence of method performance for its intended use. Our validation protocols are designed around the method type, analyte characteristics, and project stage.
Method transfer is the documented process of demonstrating that a receiving laboratory can execute an analytical method with equivalent reliability to the originating site. BOC Sciences supports both sending and receiving roles with structured transfer protocols.
BOC Sciences delivers method development, validation, and transfer as an integrated workflow—from early feasibility through cross-laboratory implementation—with rigorous data, responsive communication, and a focus on methods that perform consistently in real laboratory settings.
BOC Sciences applies method development, validation, and transfer expertise across a broad range of pharmaceutical analysis projects. Each category is supported with tailored method design, appropriate analytical technologies, and project-specific validation and transfer strategies.
| Project Category | BOC Sciences Support |
| Drug Substance and Intermediate Analysis | Development of assay, purity, related substance, residual solvent, chiral purity, and identity confirmation methods for APIs, peptides, and synthetic intermediates. Full validation and transfer support for release and stability testing. |
| Drug Product and Formulation Analysis | Development of content uniformity, assay, dissolution, and degradation product methods for tablets, capsules, injectables, topicals, and oral solutions. Method design includes excipient interference screening and formulation-specific sample preparation. |
| Impurity and Degradation Product Analysis | Development of selective methods for organic impurities, process impurities, and degradation products. Includes column and mobile phase screening, impurity identification by LC-MS or GC-MS, quantification method validation, and forced degradation study execution. |
| Stability-Indicating Method Development | Forced degradation studies under acid, base, oxidative, thermal, and photolytic conditions; peak purity and mass balance assessment; method refinement to achieve baseline resolution of all degradants; full validation of stability-indicating capability. |
| Cleaning Residue Analysis | Method development with sensitivity appropriate for residue limits; swab and rinse sampling procedure development and recovery studies; validation covering LOD/LOQ, accuracy, and precision at trace residue levels. |
| Complex Matrix and Biomolecule Analysis | Matrix-specific sample preparation (extraction, digestion, clean-up) for peptides, oligonucleotides, conjugates, liposomes, lipid nanoparticles, and polymer-based delivery systems. Method design addressing matrix interference and analyte recovery, with validation in the target matrix. |
Our chromatographic testing capabilities support separation, detection, and quantitation across diverse analytes and matrices.
Our mass spectrometry testing capabilities support identity confirmation, selective quantitation, impurity investigation, and structural interpretation.
Our spectroscopic testing capabilities provide rapid measurement, structural information, and orthogonal confirmation.
Classical and instrument-assisted measurements complement separation and spectroscopic methods when the project depends on material or solution properties.
Validation characteristics are selected according to the method's intended use, analyte level, matrix, and decision risk. The study design may also incorporate robustness, carryover, sample-solution stability, filter compatibility, and system-suitability evaluation when relevant to dependable execution.
We evaluate whether the procedure can measure the target analyte in the presence of components that may reasonably occur in the sample. Depending on the project, testing may include blank, placebo, matrix, starting material, impurity, degradant, solvent, reagent, or co-administered component challenges. Chromatographic resolution, peak purity, ion transitions, spectral comparison, or orthogonal measurements are used as appropriate.
Accuracy is assessed by comparing measured results with known, reference, or independently established values, often across relevant concentration levels and matrix conditions. Precision evaluates variability within the procedure through replicate preparation and measurement. Study design may examine repeatability and intermediate sources of variation such as analyst, day, instrument, column, reagent lot, or sample-preparation sequence.
We assess the relationship between analyte level and analytical response across the interval needed for the method. Evaluation considers calibration model, number and distribution of levels, replicate measurements, residual behavior, weighting where appropriate, and back-calculated performance. The analytical range is established from the combined evidence for response behavior, accuracy, precision, and the method's intended application.
Detection and quantitation capability can be estimated from signal behavior, calibration statistics, or analyte response, then confirmed experimentally when the project requires dependable low-level measurement. We consider baseline noise, matrix contribution, recovery, precision, accuracy, integration consistency, carryover, and analyte stability so that the reported limit reflects practical method performance rather than an isolated instrument response.
Share your analyte information, method type, sample matrix, and project stage. Our team will propose a validation protocol with appropriate performance parameters, acceptance criteria, and a timeline that matches your development needs and data expectations.
BOC Sciences begins each project with a structured review of the analyte, sample matrix, method purpose, target performance criteria, available reference materials, and any prior method history. A project plan is then prepared covering method approach, resource allocation, timeline, and communication points between our team and the client.
Our scientists select the analytical technique and initial conditions based on the analyte's physicochemical properties, then perform systematic parameter screening to identify the most influential variables. Conditions are iteratively refined until the method meets pre-defined development goals for selectivity, sensitivity, peak shape, and analysis time. When needed, forced degradation samples are used to guide stability-indicating method development.
Once the method is developed, BOC Sciences executes a formal validation protocol covering the relevant performance parameters. Data from each validation experiment is reviewed against pre-defined acceptance criteria. Any deviations are investigated, documented, and resolved before the validation package is finalized and reported.
For method transfer projects, BOC Sciences coordinates comparative testing between the originating and receiving laboratories, reviews results against pre-defined transfer acceptance criteria, and prepares a transfer summary report. All project data—including chromatograms, spectra, raw data tables, and statistical analyses—are compiled into a comprehensive documentation package for client review and record-keeping.
Co-elution of the target analyte with impurities, degradation products, or formulation excipients is one of the most common challenges in pharmaceutical method development. This issue can lead to inaccurate assay values, missed impurity peaks, or unreliable stability data. BOC Sciences addresses selectivity challenges by systematically screening stationary phases with different selectivity characteristics, adjusting mobile phase pH to exploit differences in analyte ionization, evaluating organic modifier type and gradient profile, and testing alternative detection modes such as mass spectrometry or charged aerosol detection when UV chromophores overlap. For particularly difficult separations, we explore orthogonal separation mechanisms including HILIC, ion-pair chromatography, and mixed-mode phases to achieve the necessary resolution.
Methods requiring trace-level detection—such as those for genotoxic impurities, cleaning residues, or low-dose formulations—often struggle with inadequate signal-to-noise ratios, drifting baselines, or inconsistent detector response across runs. BOC Sciences improves detection sensitivity by optimizing injection volume and sample concentration, selecting the most sensitive detection wavelength, evaluating fluorescence or mass spectrometric detection when UV sensitivity is insufficient, and fine-tuning detector parameters such as gain, slit width, and data acquisition rate. For methods showing response drift, we investigate mobile phase stability, column equilibration, lamp aging, and environmental factors to identify and resolve the root cause of instability.
Complex matrices—such as creams, ointments, lipid-based formulations, polymer drug delivery systems, and biological media—introduce matrix components that can suppress analyte response, cause baseline disturbances, or foul chromatographic columns over repeated injections. BOC Sciences develops matrix-appropriate sample preparation strategies including liquid-liquid extraction, solid-phase extraction with sorbent screening, protein precipitation, dilution optimization, and filtration method selection. We evaluate recovery at each sample preparation step and compare matrix-matched standards against neat standards to identify and correct for matrix effects before the method proceeds to validation.
When a method performs well in the development laboratory but produces variable results when transferred to a different analyst, instrument, or quality control site, the underlying cause often involves unrecognized method sensitivity to operational factors. BOC Sciences investigates these inconsistencies by identifying the critical method parameters that most affect results, evaluating instrument-to-instrument variability in dwell volume, detector response, and column temperature control, and assessing analyst-dependent steps such as sample preparation timing, injection technique, and integration practices. We then refine the method procedure, tighten system suitability criteria, and add procedural detail to the method description to improve inter-laboratory and inter-analyst consistency.
Describe your current method difficulty—whether it is selectivity, sensitivity, robustness, or transfer—and our analytical team will propose a targeted approach built on broad technology coverage and deep method development experience.
BOC Sciences supports analytical methods from initial development through validation and cross-laboratory transfer, providing continuity that reduces the risk of knowledge loss between project stages. Our team handles method feasibility assessment, development, optimization, validation protocol execution, transfer coordination, and post-transfer troubleshooting—all within a single integrated workflow. This lifecycle perspective means that validation and transfer considerations are built into the method from the start, rather than addressed reactively after development is complete.
Every method we develop is designed with its end use in mind. A dissolution method for quality control requires different design priorities than an impurity profiling method for process development support. We define the analytical target profile early in each project—specifying what the method must measure, at what level, in what matrix, and under what operational constraints—then select separation mode, detection technology, and validation parameters accordingly. This purpose-first approach produces methods that are fit for their intended application rather than over- or under-engineered.
With capabilities spanning HPLC/UHPLC with multiple detection modes, GC with headspace and liquid injection, LC-MS and LC-MS/MS platforms, NMR spectroscopy, and a full range of physicochemical testing techniques, BOC Sciences can select the most appropriate analytical technology for each project rather than adapting the project to fit a limited instrument set. Our analytical platform supports method development for diverse analyte types including small molecules, peptides, oligonucleotides, and conjugated compounds. For projects requiring specialized techniques, we also provide comprehensive analytical technology support that covers hyphenated and orthogonal approaches.
Clients working with BOC Sciences receive more than final results; they receive organized, reviewable data packages with clear documentation of method conditions, validation outcomes, and any deviations encountered. We maintain responsive technical communication throughout each project, providing updates at key milestones and discussing results in the context of the client's broader development goals. This communication approach helps clients make informed decisions about method readiness, transfer timing, and follow-up activities without waiting for the final report.
Client Needs: A pharmaceutical development team required a stability-indicating HPLC method for a small-molecule API with a complex degradation profile. The compound contained a hydrolytically labile ester group and a photolabile aromatic ring, generating multiple degradation products under stress conditions. The existing method could not resolve three degradation peaks from the API, and one degradant co-eluted with a process-related impurity.
Challenges: The primary difficulty was achieving baseline separation between the API and two early-eluting degradation products that exhibited nearly identical retention on standard C18 phases. Additionally, a photodegradation product showed strong solvent-dependent peak splitting that complicated quantification.
Solution: We screened six stationary phases with differing selectivity, including phenyl-hexyl, pentafluorophenyl, and polar-embedded C18 columns, evaluating each with stressed samples containing the full degradation profile. Mobile phase pH was scouted from 2.5 to 7.0, and the gradient slope was adjusted across 15 runs to optimize the critical separation window. Detection wavelength was selected after acquiring UV spectra for the API and each degradation product. The optimized method used a phenyl-hexyl column with a shallow gradient at pH 3.5, achieving baseline resolution for all 11 peaks. Specificity was confirmed across acid, base, oxidative, thermal, and photolytic stress conditions. Validation covered specificity, linearity (50–150% of nominal), accuracy (recovery 98–102% at three levels), precision (RSD<1.5% for repeatability), and LOD/LOQ.
Outcome: The client received a fully validated stability-indicating method with documented resolution of all degradation products, a complete validation data package, and a method procedure suitable for immediate implementation in their stability program.
Client Needs: A drug product manufacturer needed to transfer a validated impurity method for a peptide drug product from their R&D laboratory to a quality control site operating different instrument models. The method involved gradient RP-HPLC with UV detection and included quantification of three process-related impurities at reporting threshold levels.
Challenges: The receiving laboratory used HPLC systems with a different dwell volume and detector flow cell geometry, resulting in retention time shifts of up to 1.2 minutes and altered relative response factors for two impurities. An early transfer attempt had failed to meet the pre-defined acceptance criteria for impurity quantitation accuracy.
Solution: We first characterized the dwell volume difference between the two instrument models and adjusted the gradient timetable to compensate. Detector response was normalized using a calibration transfer approach with six concentration levels run on both systems. The sample preparation procedure was reviewed and clarified, with specific guidance added on dissolution solvent temperature and filtration steps. Comparative testing was then conducted with three API batches and spiked impurity samples, generating 18 paired results across the two laboratories. All results met the acceptance criteria for retention time matching, resolution, and impurity content agreement.
Outcome: The method was successfully implemented at the receiving laboratory with documented equivalency to the originating site. The transfer report included instrument-specific adjustments, normalized system suitability criteria, and a refined sample preparation procedure that supported consistent execution.
The team quickly identified that our separation problem came from the combined effects of sample solvent and mobile-phase pH. Their structured experiments gave us a clearer method-development path and avoided repeated changes without a defined rationale.
— A Senior Analytical Scientist in the United States
The validation results were organized by parameter, acceptance criterion, and conclusion, which made the data easy for our project team to review. Questions about atypical observations were addressed with the relevant chromatograms and experimental context.
— An Analytical Development Manager in Germany
BOC Sciences helped both laboratories focus on the variables that actually affected method performance. The instrument comparison, method walkthrough, and shared data review made it much easier to resolve the initial differences in retention and integration.
— A Process Analytics Lead in the United Kingdom
Project updates were concise and technically useful. When matrix interference appeared in a new sample type, the team explained the evidence, proposed focused experiments, and helped us choose a practical adjustment to the sample-preparation procedure.
— A Formulation Project Scientist in Switzerland
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
